Structures of the ATP-fueled ClpXP proteolytic machine bound to protein substrate

  1. Xue Fei
  2. Tristan A Bell
  3. Simon Jenni
  4. Benjamin M Stinson
  5. Tania A Baker
  6. Stephen C Harrison
  7. Robert T Sauer  Is a corresponding author
  1. Massachusetts Institute of Technology, United States
  2. Harvard Medical School, United States
  3. Howard Hughes Medical Institute, Harvard Medical School, United States

Abstract

ClpXP is an ATP-dependent protease in which the ClpX AAA+ motor binds, unfolds, and translocates specific protein substrates into the degradation chamber of ClpP. We present cryo-EM studies of the E. coli enzyme that show how asymmetric hexameric rings of ClpX bind symmetric heptameric rings of ClpP and interact with protein substrates. Subunits in the ClpX hexamer assume a spiral conformation and interact with two-residue segments of substrate in the axial channel, as observed for other AAA+ proteases and protein-remodeling machines. Strictly sequential models of ATP hydrolysis and a power stroke that moves two residues of the substrate per translocation step have been inferred from these structural features for other AAA+ unfoldases, but biochemical and single-molecule biophysical studies indicate that ClpXP operates by a probabilistic mechanism in which five to eight residues are translocated for each ATP hydrolyzed. We propose structure-based models that could account for the functional results.

Data availability

PDB files for the structures determined here have been deposited in the PDB under accession codes 6PPE, 6PP8, 6PP7, 6PP6, 6PP5, 6POS, 6POD, 6PO3, and 6PO1.

The following data sets were generated
    1. Fei et al
    (2020) 6PPE
    RCSB Protein Data Bank, 6PPE.
    1. Fei et al
    (2020) 6PP8
    RCSB Protein Data Bank, 6PP8.
    1. Fei et al
    (2020) 6PP7
    RCSB Protein Data Bank, 6PP7.
    1. Fei et al
    (2020) 6PP6
    RCSB Protein Data Bank, 6PP6.
    1. Fei et al
    (2020) 6PP5
    RCSB Protein Data Bank, 6PP5.
    1. Fei et al
    (2020) 6POS
    RCSB Protein Data Bank, 6POS.
    1. Fei et al
    (2020) 6POD
    RCSB Protein Data Bank, 6POD.
    1. Fei et al
    (2020) 6PO3
    RCSB Protein Data Bank, 6PO3.
    1. Fei et al
    (2020) 6PO1
    RCSB Protein Data Bank, 6PO1.

Article and author information

Author details

  1. Xue Fei

    Department of Biology, Massachusetts Institute of Technology, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Tristan A Bell

    Department of Biology, Massachusetts Institute of Technology, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3668-8412
  3. Simon Jenni

    Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Benjamin M Stinson

    Department of Biology, Massachusetts Institute of Technology, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Tania A Baker

    Department of Biology, Massachusetts Institute of Technology, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0737-3411
  6. Stephen C Harrison

    Howard Hughes Medical Institute, Harvard Medical School, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7215-9393
  7. Robert T Sauer

    Department of Biology, Massachusetts Institute of Technology, Cambridge, United States
    For correspondence
    bobsauer@mit.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1719-5399

Funding

National Institutes of Health (GM-101988)

  • Robert T Sauer

Howard Hughes Medical Institute

  • Tania A Baker
  • Stephen C Harrison

National Institutes of Health (5T32GM-007287)

  • Tristan A Bell

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Fei et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 6,749
    views
  • 929
    downloads
  • 108
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Xue Fei
  2. Tristan A Bell
  3. Simon Jenni
  4. Benjamin M Stinson
  5. Tania A Baker
  6. Stephen C Harrison
  7. Robert T Sauer
(2020)
Structures of the ATP-fueled ClpXP proteolytic machine bound to protein substrate
eLife 9:e52774.
https://doi.org/10.7554/eLife.52774

Share this article

https://doi.org/10.7554/eLife.52774

Further reading

    1. Structural Biology and Molecular Biophysics
    Xinyu Gu, Akashnathan Aranganathan, Pratyush Tiwary
    Research Article

    Small-molecule drug design hinges on obtaining co-crystallized ligand-protein structures. Despite AlphaFold2’s strides in protein native structure prediction, its focus on apo structures overlooks ligands and associated holo structures. Moreover, designing selective drugs often benefits from the targeting of diverse metastable conformations. Therefore, direct application of AlphaFold2 models in virtual screening and drug discovery remains tentative. Here, we demonstrate an AlphaFold2-based framework combined with all-atom enhanced sampling molecular dynamics and Induced Fit docking, named AF2RAVE-Glide, to conduct computational model-based small-molecule binding of metastable protein kinase conformations, initiated from protein sequences. We demonstrate the AF2RAVE-Glide workflow on three different mammalian protein kinases and their type I and II inhibitors, with special emphasis on binding of known type II kinase inhibitors which target the metastable classical DFG-out state. These states are not easy to sample from AlphaFold2. Here, we demonstrate how with AF2RAVE these metastable conformations can be sampled for different kinases with high enough accuracy to enable subsequent docking of known type II kinase inhibitors with more than 50% success rates across docking calculations. We believe the protocol should be deployable for other kinases and more proteins generally.

    1. Structural Biology and Molecular Biophysics
    Dipti Ranjan Lenka, Shakti Virendra Dahe ... Atul Kumar
    Research Article

    Loss-of-function Parkin mutations lead to early-onset of Parkinson’s disease. Parkin is an auto-inhibited ubiquitin E3 ligase activated by dual phosphorylation of its ubiquitin-like (Ubl) domain and ubiquitin by the PINK1 kinase. Herein, we demonstrate a competitive binding of the phospho-Ubl and RING2 domains towards the RING0 domain, which regulates Parkin activity. We show that phosphorylated Parkin can complex with native Parkin, leading to the activation of autoinhibited native Parkin in trans. Furthermore, we show that the activator element (ACT) of Parkin is required to maintain the enzyme kinetics, and the removal of ACT slows the enzyme catalysis. We also demonstrate that ACT can activate Parkin in trans but less efficiently than when present in the cis molecule. Furthermore, the crystal structure reveals a donor ubiquitin binding pocket in the linker connecting REP and RING2, which plays a crucial role in Parkin activity.